Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GNP 101

Drug Profile

GNP 101

Alternative Names: anti-HER2-IFN-beta mutein immunocytokine - Genopharm; GNP-101; trastuzumab-IFN-ß mutein - Genopharm

Latest Information Update: 02 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genopharm
  • Class Antineoplastics; Immunotherapies; Interferons; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Interferon beta replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 May 2023 GNP 101 is available for licensing as of 24 May 2023. http://www.genopharmbio.com/web/home.php?go=page2.0&mid=11 (Genopharm website, May 2023)
  • 24 May 2023 Geropharm plans a phase I trial for Breast cancer and Gastric cancer in 2025 (Parenteral) (Geropharm pipeline, May 2023)
  • 24 May 2023 Geropharm plans a phase II trial for Breast cancer and Gastric cancer in 2027 (Parenteral) (Geropharm pipeline, May 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top